|Day Low/High||61.25 / 63.28|
|52 Wk Low/High||28.00 / 65.43|
It is incredibly healthy to see so many stocks so strong, from so many sectors.
Bearish names dominate this week and financials in particular.
This large-cap rally isn't fizzling out -- it's heating up.
For all the talk of rising rates the yield on the benchmark 10-year Treasury has remain stuck. That keeps dividend paying stocks in the spotlight.
Forget starting the year with a juice cleanse. Kick-off 2017 with a 'financial cleanse' and the results will last far longer.
According to KBW, these financial stocks are your best bets for 2017.
Most likely is a bit of sideways-to-lower action rather than a deep pullback.
The speed at which stocks surged after Donald Trump's presidential win runs the risk of a pullback, according to Charles Schwab's chief investment strategist Liz Ann Sonders.
Four Large Cap Stocks Ready to Rebound: Home Depot, Celgene, Charles Schwab and Allergan
Alphabet shares rose after EU regulators granted the company additional time to formally respond to the EU Commission's latest antitrust allegations.
TIPS, Floating-rate investments are best while waiting for Fed's likely December move.
Don't expect the Federal Reserve to hike interest rates next week. They are way too cautious to rock the boat with inflation still so low.
Charles Schwab has a new target in the battle for your retirement dollars.
Charles Schwab's chief investment strategist, Liz Ann Sonders thinks the bull market has some steam left.
Interactive Brokers will likely steal business away from firms like Fidelity and TD Ameritrade in the future.
These names are now oversold and are sitting at attractive prices.
Perhaps it's 'gulit by association,' but opportunities can be found in this sector.
Global markets were sent into a tailspin Friday following the U.K.'s decision to exit the European Union.
The yield curve continues to flatten as the Federal Reserve stays on the sidelines, making it hard for bond investors.
Brace for another rate hike from the Federal Reserve within the next two months, according to Charles Schwab's Liz Ann Sonders.
Things could get far worse before they get better for high yield bond investors, said Collin Martin, fixed income director at the Schwab Center for Financial Research.
With central bank policies set to diverge, volatility, credit spreads and market overreactions will continue to distract investors in 2016.
Like many big caps, both stocks just haven't fallen enough yet.
Shares of Pfizer were essentially flat in 2015, but the pharmaceutical giant’s decision in November to buy Allergan in a deal worth $160 billion made huge waves.
The recent selloff makes the group that much more attractive for 2016.